Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 16, 2009

PPD Opens Lab in Singapore to Support Demand in Southeast Asia

  • Contract research organization PPD opened a new global central laboratory facility at the Singapore Science Park II. The new site is expected to boost the company’s provision of customizable laboratory services in Southeast Asia.

    PPD has operated an office in Singapore for over 10 years to provide clients with clinical development services, clinical trials management monitoring, patient recruitment, and regulatory affairs services. The company says that the new Singapore site houses identical laboratory instrumentation to that at its other global central labs in Brussels, Beijing, and Highland Heights, KY. This will facilitate the cross-validation of assays between all its locations. The Singapore lab will also interface with ConneXion, PPD’s global database.

    2009 has already seen PPD acquire AbC.R.O, a contract research organization operating in Central and Eastern Europe. The company separately established a new office in Tokyo to expand its Phase II–IV clinical development services in response to client demand in East Asia. In April PPD also bought Massachusetts-based dermatology therapeutics company, Magen, and announced an agreement to sell its existing Piedmont Research Center to Charles River Laboratories International for $46 million in cash.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »